License out our drugs

You are here

Your partner for healthcare innovation

 

Our business model involves drug discovery and development. After clinical proof-of-concept, Iproteos then licenses out the drugs to third parties to ensure that they reach patients.

At Iproteos, we study and develop new drugs to treat diseases with great social impact, with the determination to improve the health of millions of people. 

  • Cutting-edge science: we are one of the few biotechnology companies in the world that specialises in PPI modulators
  • Innovative products in the pipeline
  • Our team comprises people with relevant international experience and extensive track record
  • High returns and social impact

For further information, please contact us.